Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Downer wins long-term maintenance contract

2018-07-16 australianmining.com.au
Chevron has awarded Downer EDI a five-year contract to provide maintenance and support services at its Western Australian operations.
DOW DNERY DOW

5
Receivers probe 13 ex-Hawkins companies, call for creditors issued

2018-05-30 nzherald.co.nz
The receivers of 13 businesses previously part of New Zealand's second-largest construction company Hawkins are calling for creditors and say the directors of the businesses are giving their full support in the process.
DOW DNERY DOW

5
Ex-Hawkins Orange-H placed in receivership by shareholder; owes creditors $30 million

2018-05-11 nzherald.co.nz
Orange-H Group, the McConnell entity set up to run down the residual Hawkins assets after the sale to Downer Group, has been tipped into receivership by its shareholder and creditor just 10 days after being ordered to pay $13.4 million over a leaky school.
DOW DNERY DOW

5
OZ closes Prominent Hill open pit

2018-04-17 australianmining.com.au
OZ Minerals has completed its planned closure of the Prominent Hill open pit in South Australia.
DOW OZMLF DNERY AVB DOW OZL

5
OZ Minerals awards $660m Carrapateena contract to Downer

2018-04-16 australianmining.com.au
Downer EDI will deliver underground mining services at OZ Minerals’ Carrapateena copper-gold project in South Australia after being awarded a $660 million contract at the operation.
DOW OZMLF DNERY DOW OZL

5
New Century awards ‘landmark’ training contract at Century mine

2018-03-28 australianmining.com.au
New Century Resources has awarded what has been described as a landmark contract to the Waanyi ReGen Joint Venture (WRJV) to provide training services for Aboriginal and Torres Strait Islander people local to the Century zinc mine in Queensland.
DOW DNERY DOW NCRE

21
CIMIC joins BHP, Rio on LinkedIn top companies list

2018-03-21 australianmining.com.au
CIMIC Group is the first of several mining and related services companies that have been named in LinkedIn’s 2018 Top Companies list for Australia.
CIM DOW RTPPF RIO RIO DNERY RIO DOW RTNTF LGTHF LGTHY

Related Articles

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

CUSIP: 260737101